iTeos Therapeutics (ITOS) Earnings Date, Estimates & Call Transcripts $7.42 +0.20 (+2.77%) (As of 12/20/2024 05:30 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends iTeos Therapeutics Latest Earnings SummaryActual EPS (Nov. 12) -$1.05 Beat By $0.13 Consensus EPS (Nov. 12) -$1.18 iTeos Therapeutics announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.05, which beat the consensus estimate of -$1.18 by $0.13. With a trailing EPS of -$3.15, iTeos Therapeutics' earnings are expected to decrease next year, from ($3.46) to ($4.72) per share. Get iTeos Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iTeos Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataITOS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ITOS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. iTeos Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$1.22-$0.89-$1.06Q2 20242-$1.15-$0.99-$1.07Q3 20242-$1.21-$1.11-$1.16Q4 20242-$1.25-$0.95-$1.10FY 20248-$4.83-$3.94-$4.39Q1 20252-$1.40-$1.01-$1.21Q2 20252-$1.52-$1.13-$1.33Q3 20252-$1.64-$1.19-$1.42Q4 20252-$1.78-$1.23-$1.51FY 20258($6.34)($4.56)($5.45) iTeos Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/12/2024--$1.18-$1.05+$0.13-$1.05--8/8/2024--$1.04-$0.18+$0.86-$0.18$4.20M$35.00M5/10/2024Q1 2024-$1.02-$1.07 -$0.05-$1.07--3/6/2024Q4 2023-$1.03-$0.85+$0.18-$0.85$37.41M-11/7/2023Q3 2023-$1.20-$0.90+$0.30-$0.90--8/8/2023Q2 2023-$1.03-$0.96+$0.07-$0.96-- Get the Latest News and Ratings for ITOS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/10/2023Q1 2023-$0.99-$0.44+$0.55-$0.44$13.80M$12.60M3/15/2023Q4 2022$0.42$0.57+$0.15$0.57$41.16M$53.91M iTeos Therapeutics Earnings - Frequently Asked Questions When did iTeos Therapeutics announce their last quarterly earnings? iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earning data on Tuesday, November 12, 2024. Learn more on ITOS's earnings history. Did iTeos Therapeutics beat their earnings estimates last quarter? In the previous quarter, iTeos Therapeutics (NASDAQ:ITOS) reported ($1.05) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.18) by $0.13. Learn more on analysts' earnings estimate vs. ITOS's actual earnings. How much revenue does iTeos Therapeutics generate each year? iTeos Therapeutics (NASDAQ:ITOS) has a recorded annual revenue of $35 million. How much profit does iTeos Therapeutics generate each year? iTeos Therapeutics (NASDAQ:ITOS) has a recorded net income of -$112.64 million. ITOS has generated -$3.15 earnings per share over the last four quarters. What is iTeos Therapeutics's EPS forecast for next year? iTeos Therapeutics's earnings are expected to decrease from ($3.46) per share to ($4.72) per share in the next year. More Earnings Resources from MarketBeat Related Companies Rocket Pharmaceuticals Earnings Bicycle Therapeutics Earnings Avadel Pharmaceuticals Earnings Collegium Pharmaceutical Earnings Zymeworks Earnings Bicara Therapeutics Earnings Gyre Therapeutics Earnings Poseida Therapeutics Earnings Phibro Animal Health Earnings Cogent Biosciences Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Did You See Trump’s Bombshell Exec. Order 001? (Ad)Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. This page (NASDAQ:ITOS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
